BACKGROUND: Surgical resections for invasive ductal adenocarcinoma of the pancreas can provide the only chance of cure, although the 5-year survivors are not always equated with cure. METHODS: A total of 229 who underwent a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma between 1990 and 2003 and have been observed for more than 5 years from the time of resection were retrospectively analyzed. The data of patients who survived more than 5 years were compared with those died within 5 years. The recurrence pattern and factors that influenced an additional 5-year survival in the 5-year survivors were investigated. RESULTS: Forty patients (17%) survived more than 5 years, and the survival rate for an additional 5 years after surviving 5 years was 72%. A multivariate Cox hazards analysis showed that negative surgical margins status, less frequency of lymphatic invasion, stage </= IIB, and negative lymph node involvement were independent factors associated with long-term survival. Thirty patients (75%) were alive without recurrence, and eight (20%) died of disease within 7.3 years. Intrapancreatic nerve invasion was a significant factor predicting additional long-term survival in the 40 5-year survivors. CONCLUSIONS: Limited cancer extension with negative lymph node metastases significantly contributes to the chance of surviving more than 5 years. A low incidence of intrapancreatic nerve invasion in the 5-year survivors affects the subsequent favorable survival.
BACKGROUND: Surgical resections for invasive ductal adenocarcinoma of the pancreas can provide the only chance of cure, although the 5-year survivors are not always equated with cure. METHODS: A total of 229 who underwent a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma between 1990 and 2003 and have been observed for more than 5 years from the time of resection were retrospectively analyzed. The data of patients who survived more than 5 years were compared with those died within 5 years. The recurrence pattern and factors that influenced an additional 5-year survival in the 5-year survivors were investigated. RESULTS: Forty patients (17%) survived more than 5 years, and the survival rate for an additional 5 years after surviving 5 years was 72%. A multivariate Cox hazards analysis showed that negative surgical margins status, less frequency of lymphatic invasion, stage </= IIB, and negative lymph node involvement were independent factors associated with long-term survival. Thirty patients (75%) were alive without recurrence, and eight (20%) died of disease within 7.3 years. Intrapancreatic nerve invasion was a significant factor predicting additional long-term survival in the 40 5-year survivors. CONCLUSIONS: Limited cancer extension with negative lymph node metastases significantly contributes to the chance of surviving more than 5 years. A low incidence of intrapancreatic nerve invasion in the 5-year survivors affects the subsequent favorable survival.
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: T A Sohn; C J Yeo; J L Cameron; L Koniaris; S Kaushal; R A Abrams; P K Sauter; J Coleman; R H Hruban; K D Lillemoe Journal: J Gastrointest Surg Date: 2000 Nov-Dec Impact factor: 3.452
Authors: Taylor S Riall; John L Cameron; Keith D Lillemoe; Jordan M Winter; Kurtis A Campbell; Ralph H Hruban; David Chang; Charles J Yeo Journal: Surgery Date: 2006-08-28 Impact factor: 3.982
Authors: James Helm; Barbara A Centeno; Domenico Coppola; Marcovalerio Melis; Mark Lloyd; Jong Y Park; Dung-Tsa Chen; Mokenge P Malafa Journal: Cancer Date: 2009-09-15 Impact factor: 6.860
Authors: Karyn B Stitzenberg; James Christopher Watson; Andrew Roberts; Steven A Kagan; Steven J Cohen; Andre A Konski; John P Hoffman Journal: Ann Surg Oncol Date: 2008-03-05 Impact factor: 5.344
Authors: Mechteld C de Jong; Fuyu Li; John L Cameron; Christopher L Wolfgang; Barish H Edil; Joseph M Herman; Michael A Choti; Frederick Eckhauser; Kenzo Hirose; Richard D Schulick; Timothy M Pawlik Journal: J Surg Oncol Date: 2011-01-31 Impact factor: 3.454
Authors: Veronica G Onete; Marc G Besselink; Chanielle M Salsbach; Casper H Van Eijck; Olivier R Busch; Dirk J Gouma; Ignace H de Hingh; Egbert Sieders; Cornelis H Dejong; Johan G Offerhaus; I Quintus Molenaar Journal: HPB (Oxford) Date: 2015-06-02 Impact factor: 3.647
Authors: Marco Dal Molin; Ming Zhang; Roeland F de Wilde; Niki A Ottenhof; Neda Rezaee; Christopher L Wolfgang; Amanda Blackford; Bert Vogelstein; Kenneth W Kinzler; Nickolas Papadopoulos; Ralph H Hruban; Anirban Maitra; Laura D Wood Journal: Clin Cancer Res Date: 2015-01-26 Impact factor: 12.531
Authors: Cristina A Metildi; Sharmeela Kaushal; Chanae R Hardamon; Cynthia S Snyder; Minya Pu; Karen S Messer; Mark A Talamini; Robert M Hoffman; Michael Bouvet Journal: J Am Coll Surg Date: 2012-05-24 Impact factor: 6.113
Authors: Stephen Y Oh; Alicia Edwards; Margaret T Mandelson; Bruce Lin; Russell Dorer; W Scott Helton; Richard A Kozarek; Vincent J Picozzi Journal: World J Gastroenterol Date: 2015-12-28 Impact factor: 5.742
Authors: Cristina A Metildi; Sharmeela Kaushal; Minya Pu; Karen A Messer; George A Luiken; Abdool R Moossa; Robert M Hoffman; Michael Bouvet Journal: Ann Surg Oncol Date: 2014-02-06 Impact factor: 5.344